Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Breast Cancer Drug May Help Healthy Women

        A DGReview of :"Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-inflammatory Effect"
        Arteriosclerosis, Thrombosis, and Vascular Biology

        02/21/2001
        By Anne MacLennan


        Tamoxifen has been found to have effects on inflammatory markers that are consistent with reduced cardiovascular risk.

        This finding, from a multi-centre study, is in contrast to recent reports of increased C-reactive protein linked with postmenopausal estrogen. It also suggests the potential for beneficial cardiovascular effects of this drug in healthy women.

        Although tamoxifen reduces incidences of breast cancer in women who are at risk for that disease, it is also associated with venous thrombosis.

        This, together with the fact that heart disease is the leading cause of death in women, prompted the current investigation of the link between tamoxifen and cardiovascular risk factors.

        Contributing researchers were from the University of Vermont, Burlington, Vermont; University of Pittsburgh, Pittsburgh, Pennsylvania; and Virginia Commonwealth University, Richmond, Virginia, all in the United States.

        Researchers enrolled 111 healthy women at a single centre who were participating in a randomized, double-blind, breast cancer prevention trial.

        Researchers compared the six-month effects of oral tamoxifen (20 mg/d) versus placebo on factors related to inflammation, hemostatis and lipids.

        Tamoxifen was found to be linked with reductions of 26 percent in median C-reactive protein, 22 percent in median fibrinogen and nine percent in cholesterol compared to placebo.

        No differences were found in treatment effects on factor VII coagulant activity, fragment 1-2 or triglycerides.

        In further analyses, the effect of tamoxifen on C-reactive protein was larger in postmenopausal women and in those with higher waist-to-hip ratios.

        It was also larger in women with higher baseline cholesterol.

        These researchers conclude that the effects shown on inflammatory markers by tamoxifen were consistent with reduced cardiovascular risk and suggest the potential for beneficial effects with this drug in healthy women.
        Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:255. "Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-inflammatory Effect"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send